Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Mantle-Cell

Explore clinical trials studying Lymphoma, Mantle-Cell. Study availability and eligibility vary by location and protocol.

38 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Mantle-Cell trial results

Completed

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

NCT05564052

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Santa Casa de Misericordia de Belo Horizonte Belo Horizonte, Brazil
  • Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia Brasília, Brazil
  • Ynova Pesquisa Clinica Florianópolis, Brazil
  • Liga Norte Riograndense Contra O Cancer Natal, Brazil
View all 66 locations
View Trial Details
Completed

A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)

NCT02278796

Conditions
Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, Histiocytic Disorders, Malignant, +13 more
Locations
  • Krankenhaus der Elisabethinen Linz Linz, Austria
  • Hanusch Krankenhaus Wien Vienna, Austria
  • Department for Medical Oncology University Hospital/Inselspital Bern, Switzerland
  • Universitätsspital Zürich Zurich, Switzerland
View Trial Details
Completed

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

NCT03190330

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +16 more
Locations
  • Avron Hospitals Pvt. Ltd Ahmedabad, India
  • Post Graduate Institute of Medical Education And Research PGIMER Chandigarh, India
  • Basavatarakam Indo-American Hospital Hyderabad, India
  • Bhagwan Mahaveer Cancer Hospital & Research Centre Jaipur, India
View Trial Details
Completed

A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea

NCT04036448

Conditions
Bone Marrow Diseases, Disease Attributes, Hematologic Diseases, +15 more
Locations
  • Local Institution - S02 Seoul, Seoul Teugbyeolsi, South Korea
  • Hallym University Medical Center Anyang, South Korea
  • Keimyung University Dongsan Hospital Daegu, South Korea
  • Kyungpook National University Hospital Daegu, South Korea
View all 26 locations
View Trial Details
Completed

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

NCT03647124

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • Local Institution - 105 Graz, Austria
  • LKH Graz Medizinische Universitätsklinik Graz, Austria
  • LKH Hochsteiermark, Standort Leoben Leoben, Austria
  • Local Institution - 104 Leoben, Austria
View all 79 locations
View Trial Details
Completed

Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India

NCT03476655

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +16 more
Locations
  • Apollo Hospitals International Limited Ahmedabad, India
  • Healthcare Global (HCG) Hospital Bangalore, India
  • Fortis Memorial Research Institute Gurgaon, India
  • Basavatarakam Indo-American Hospital Hyderabad, India
View Trial Details
Completed

Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

NCT00700258

Conditions
Carcinoma, Carcinoma, Renal Cell, Advanced, Gastrointestinal Stroma Tumors, +11 more
Locations
  • Universitätsklinikum Ulm Ulm, Baden-Wurttemberg, Germany
  • Dr. med. Harald Held Neumünster, Schleswig-Holstein, Germany
  • Dr. med. Hans Wilhelm Duebbers Ahaus, Germany
  • Dr. Ludwig Fischer von Weikersthal Amberg, Germany
View all 77 locations
View Trial Details
Completed

Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

NCT02419560

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • City of Hope Duarte, California, United States
  • Winship Cancer Institute, Emory University Atlanta, Georgia, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • University of Virginia Charlottesville, Virginia, United States
View Trial Details

Related conditions